Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Valeant's Brodalumab Faces Conflicting FDA Views On Suicide Risk

Executive Summary

Advisory committee will hear agency reviewers' different conclusions on plaque psoriasis drug's approvability due to potential psychiatric effects and whether a REMS can help mitigate the risks.


Related Content

Post-Marketing Registry, Suicidality Warning Could Be Paradox For Siliq
Valeant's Siliq Clears FDA Panel But Faces Prospect Of Post-Marketing Registry
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
More Valeant Humiliation: Will The Messiness Ever End?
AstraZeneca Unburdens Itself Of Brodalumab
Amgen Bows Out Of Partnership With AstraZeneca On Phase III Brodalumab


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst